Investment Rating - The report rates multiple companies in the healthcare sector as "Outperform," including BeiGene, China Resources Pharmaceutical, JD Health, Innovent Biologics, WuXi Biologics, and many others [1]. Core Insights - The Hong Kong healthcare sector has shown resilience, with the Hang Seng Healthcare Index gaining 72.2% year-to-date, outperforming the Hang Seng Index by 41.1 percentage points [4][28]. - The implementation of the "dual catalogs" for basic medical insurance and commercial insurance is expected to support innovation in the pharmaceutical sector, with 114 new drugs added to the basic medical insurance catalog and a success rate of 88% [5][30]. - The report highlights the strong performance of the pharmaceutical distribution and CXO sectors, with respective gains of 2.0% and 1.7% in the past week [15][29]. Summary by Sections Market Performance - The Hang Seng Healthcare Index fell by 0.7% in the week of December 1-5, 2025, underperforming the Hang Seng Index by 1.6 percentage points [4][28]. - The pharmaceutical distribution sector and CXO services performed well, with increases of 2.0% and 1.7%, respectively [15][29]. Drug Catalog Implementation - The "National Basic Medical Insurance Catalog" and the first edition of the "Commercial Insurance Innovative Drug Catalog" were released, with 114 new drugs added to the basic insurance catalog [5][30]. - The commercial insurance catalog includes 19 innovative drugs, emphasizing support for innovation and addressing the needs of the elderly and children [13][30]. Company Highlights - Notable companies that performed well include Jinxin Fertility (+7.5%), Harbour BioMed-B (+5.3%), and WuXi Biologics (+4.7%) [15][29]. - The report suggests increasing focus on companies with strong performance certainty in the CXO sector and those with stable long-term demand in medical services [15][29].

Investment Rating - The report maintains an investment rating of "Positive" for the pharmaceutical and biotechnology industry [2]. Core Viewpoints - The recent release of the "Medical Insurance + Commercial Insurance Dual Directory" by the National Medical Insurance Administration is expected to boost investment enthusiasm for innovative drugs. The report suggests focusing on investment opportunities in innovative drugs, CXO, and the upstream life sciences industry chain [3][9]. - The pharmaceutical sector is currently experiencing a lack of clear market direction, with the pharmaceutical commercial sector leading in performance. Notable stocks include Haiwang Biological (up 55.59%), Ruikang Pharmaceutical (up 36.54%), and Yue Wannianqing (up 15.37%) [3][9]. - The report emphasizes the importance of companies with stable dividends and operational improvements, as well as potential turning points in high-end medical devices [3][11]. Summary by Sections 1. Market Performance - The pharmaceutical and biotechnology sector's return was -0.74% last week, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices. The pharmaceutical commercial sector had the highest weekly return at 5.19% [3][7]. - Over the past month, the sector's return was -2.35%, also ranking 20th among sub-industry indices, with the pharmaceutical commercial sector leading at 5.78% [3][7]. 2. Innovative Drugs - The report recommends focusing on companies with leading product pipelines and market potential, including Innovent Biologics, 3SBio, Hengrui Medicine, and others [3][9][10]. 3. CXO and Upstream Life Sciences - Key CXO companies to watch include WuXi AppTec, WuXi Biologics, and others. The report also highlights clinical CRO leaders and resource-based CXOs [10]. 4. High-End Medical Devices - The report identifies several companies in the high-end medical device sector that may benefit from market recovery and increased demand, including Mindray Medical and others [11]. 5. Valuation Metrics - The current PE (TTM) for the pharmaceutical and biotechnology industry is 29.27 times, which is below the historical average of 30.88 times over the past five years [12][15].

招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 行业及公司点评 全球市场观察 2025 年 12 月 8 日 1 中国股市上涨，港股原材料、金融与工业领涨，综合、公用事业与必选消费 下跌，南向净买入 13.4 亿港元，小米与美团净买入最多，阿里与腾讯净卖出 居前。A 股非银金融、有色金属与工贸综合涨幅居前，银行、煤炭与电信服 务跑输市场。A 股券商板块大涨，中国证监会主席表示鼓励头部机构通过并 购重组打造国际一流投行，将对优质券商适度松绑打开资本空间与杠杆限制， 鼓励中小机构打造小而美的精品投行、特色投行和特色服务商；保险板块大 涨，保险公司投资资本市场的风险因子再度下调，显示监管机构鼓励险资等 长期资本入市的态度。 美股上涨，通讯服务、信息技术与可选消费涨幅居前，公用事业、能源与医 疗保健跌幅最大。戴尔、联想、惠普等主要 OEM 厂商计划大幅提高服务器 价格，因供应很难跟上快速增长的需求。微软与博通商谈定制芯片设计合作， 可能替换现有供应商 Marvell，以降低对英伟达依赖。随着 AI 产品创新，定 制芯片需求激增，科技公司寻求供应链多元化以降低风险与成本。 美债收益率升至两周新高，美元指数转 ...

恒生指数低开0.07%，恒生科技指数涨0.08%。盘面上，科网股活跃，百度开涨3.29%，公司表示正就分 拆昆仑芯进行上市进行评估，并不保证分拆及上市将会进行。 交银国际认为，医药行业2025年迎来关键转折。2026年，该行认为板块稳中向好态势延续，但影响市场 表现的核心因素或呈分化态势。创新药方面，短期关注出海交易和业绩表现，创新迭代驱动长期价值兑 现;CXO方面，底部反转后关注行业整合趋势。值得注意的是，今日有市场传闻称，当前美国NDAA谈 判进展面临阻力。 光大证券认为，经历2025年反弹后，从估值来看，目前恒指市盈率高于过去5年均值，并向上偏离约一 个标准差，反映总体估值有所修复，但处合理区间;而科技指数刚回升至5年均值，反映估值仍有追落后 的空间。港股明年有机会再次见到30,000点以上的水平。 国信证券认为，港股短期调整为2026年市场上涨打开空间。从资金面上看，11月南向资金净流入港股市 场超1100亿元人民币。今年南向资金在港股下跌时依然逆向加仓，这既体现了内地资金的充裕流动性， 也彰显了其低位布局港股的强烈意愿。该机构预测，港股2026年有望在30000-32000点之间运行。 本文转载自腾 ...

初见睿智医药董事长胡瑞连，这位有着多次跨界创业成功经历的企业家，说话时语速平稳间透着果决。 谈及接手睿智医药的关键抉择，他回忆道："当时全行业都在打价格战，没人相信一家老牌CXO企业能 靠转型翻盘，但我始终觉得，越是红海市场，越要找到自己的专属航道。" Alling and and the management 初见睿智医药董事长胡瑞连，这位有着多次跨界创业成功经历的企业家，说话时语速平稳间透着果决。 谈及接手睿智医药的关键抉择，他回忆道："当时全行业都在打价格战，没人相信一家老牌CXO企业能 靠转型翻盘，但我始终觉得，越是红海市场，越要找到自己的专属航道。" 2025年上半年，睿智医药实现营收5.34亿元，同比增长14.75%；实现归母净利润2538.21万元，成功扭 亏为盈。而这份成绩单的背后，正是胡瑞连执掌以来推动的系统性战略布局——通过整包服务夯实市场 根基，通过技术创新构建竞争壁垒，通过全球布局打开增长空间。 近日，睿智医药在技术创新方面又迎来突破性进展。公司与华东师范大学联合发布微流智造系统，迈出 技术变革的重要一步，逐步落实战略布局。 从"零散包工"到"一站式交付" 胡瑞连的创业经历，始终带着" ...

Core Viewpoint - WuXi AppTec reported a significant increase in revenue and net profit for the first three quarters of 2025, but underlying issues such as reliance on non-recurring income, stagnant domestic growth, and reduced R&D investment pose risks to its financial health [1][6]. Group 1: Financial Performance - The company achieved a revenue of 32.857 billion yuan, representing an 18.61% year-on-year growth [1][6]. - Net profit reached 12.076 billion yuan, showing a substantial increase of 84.84% compared to the previous year [1][6]. - Non-recurring gains contributed 2.553 billion yuan to net profit, indicating a reliance on non-core income sources [2][7]. Group 2: Profit Structure Concerns - The growth in net profit is heavily influenced by non-recurring income, which accounted for over 40% of the total, raising sustainability concerns [2][8]. - After excluding non-recurring items, the adjusted net profit growth rate fell to 42.51%, lagging behind peers like Kelaiying and Kanglong Huacheng [2][7]. Group 3: Geographic Revenue Disparities - Revenue from Chinese clients grew only 0.5%, indicating stagnation in the domestic market, while revenue from U.S. clients surged by 31.9% and European revenue increased by 13.5% [3][9]. - The company's heavy reliance on the U.S. market exposes it to geopolitical risks, particularly with potential regulatory changes like the U.S. Biosecurity Act [3][9]. Group 4: Business and Financial Pressures - Internal business segments showed uneven performance, with strong growth in chemical and TIDES businesses, while testing services remained flat and other segments declined by over 10% [4][10]. - R&D expenses decreased by 13.46%, which could impact long-term competitiveness in the innovation-driven pharmaceutical industry [4][10]. - Financial pressures are evident, with financial expenses shifting from a net gain to a loss of 191 million yuan, and short-term borrowings increasing by 324.9% compared to the end of 2024 [4][10]. Group 5: Strategic Challenges Ahead - The company faces a critical juncture: whether to continue relying on non-recurring income or to enhance core business competitiveness and profitability [5][11]. - The ability to adapt to geopolitical fluctuations and diversify its client base will be crucial for sustaining innovation and project conversion efficiency [5][11].

Group 1 - The pharmaceutical industry is expected to experience a critical turning point in 2025, with a stable and positive trend continuing into 2026, influenced by factors such as policy, fundamentals, overseas investment environment, and liquidity [1] - The sector is currently undervalued, and catalysts are anticipated to drive upward momentum, with the realization of value from innovative research further pushing the overall valuation upward [1] - Stock selection will likely return to fundamentals and valuations, focusing on stocks with expected fundamental discrepancies that are still undervalued [1] Group 2 - In the innovative drug/prescription drug segment, short-term focus should be on overseas transactions and performance, with long-term value driven by innovation and iteration [2] - Key short-term catalysts include progress in overseas clinical data, inclusion in medical insurance, and reaching breakeven points, with leading Hong Kong stocks expected to maintain double-digit revenue and net profit growth [2] - Recommended stocks include: 1) 3SBio, Deking Pharmaceutical, and BeiGene, which have rich catalysts and limited impact from procurement; 2) Xiansheng Pharmaceutical, Hutchison China MediTech, and Legend Biotech, which are significantly undervalued with clear long-term growth logic [2] Group 3 - The CXO sector is expected to maintain rapid performance growth, but long-term trends indicate tightening regulations in the U.S. and increasing difficulty in new drug development, suggesting that industry consolidation may just be beginning [3] - Leading players in high-growth segments are expected to have higher long-term certainty [3] Group 4 - High-quality private hospitals are recommended as the pressure on cost control eases and outdated capacity is eliminated, allowing private medical institutions to return to a faster growth trajectory [4] - Recommended stocks include: Guoshengtang and Haijia Medical, which are expected to have short-term performance rebounds and clear long-term expansion paths [4]

Core Viewpoint - The Hang Seng Healthcare Index increased by 0.5% this week, underperforming the broader market, with the biopharmaceutical, prescription drug, and medical device sectors showing better performance than others [1] Group 1: Market Trends - Domestic investors are leaning towards defensive strategies and profit-taking, primarily increasing positions in traditional and undervalued innovative pharmaceutical companies with stable internal growth [1] - Foreign investors are more active, focusing on leading companies and upstream segments in the innovation chain, including innovative drugs and CXO targets [1] Group 2: Regulatory Changes - The transition of the procurement rules for batches 1-8 to an inquiry-based model is expected to limit overall price reductions, with the impact on Hong Kong prescription drug manufacturers likely to be less than anticipated [1] Group 3: Future Catalysts - The industry has ample catalysts in December, including various academic conferences, the announcement of healthcare negotiation results, and potential interest rate cuts by the Federal Reserve, which may stabilize investment sentiment in the sector [1] Group 4: Recommended Focus Areas - The report recommends focusing on the following segments: 1) Innovative drugs: Companies like 3SBio (01530), Eucure Biopharma (06996), and BeiGene (06160) have rich short-term catalysts and their core product values are not yet reflected in their valuations; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech (LEGN.US) are significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are benefiting from high downstream demand and marginal recovery in financing [1] 3) Hospital, medical device, and diagnostics sub-sectors are showing opportunities for reversal as regulatory uncertainties gradually ease [1]

Group 1: Technology Industry - The outlook for 2026 suggests that the artificial intelligence (AI) supercycle may continue, with strong growth in AI infrastructure expected at least until 2026, driven by significant capital expenditure increases from major cloud providers, projected to grow over 30% in 2026 following over 60% growth in 2024 and 2025 [1][2] - The report highlights a persistent supply-demand imbalance in computing acceleration and network communication chips, with overall demand remaining high despite potential increases in supply [1] - The "15th Five-Year Plan" is expected to accelerate domestic substitution opportunities in key industrial chains, supported by favorable policies during this period [1] Group 2: Semiconductor and AI Infrastructure - The recovery in terminal demand is noted to be moderate, with strong demand for servers closely related to AI, while global consumer electronics demand for 2026 is viewed with caution due to the prolonged price increases in memory chips [2] - Investment recommendations include overseas chip design and foundry companies such as NVIDIA (NVDA US), Broadcom (AVGO US), and TSMC (TSM US), which are expected to benefit from AI infrastructure development [2] - Domestic AI and substitution opportunities are also highlighted, with companies like Northern Huachuang (002371 CH), OmniVision (603501 CH), Zhongwei Company (688012 CH), and Huahong Semiconductor (1347 HK) recommended for investment [2] Group 3: Pharmaceutical Industry - The report indicates that the transition to an inquiry-based procurement model for the 1-8 batch of national procurement may limit overall price reductions, suggesting a smaller-than-expected impact on Hong Kong prescription drug companies [3] - The healthcare sector's performance is noted, with the Hang Seng Healthcare Index rising by 0.5%, although it underperformed the broader market [3] - Investment insights suggest a focus on innovative drugs and stable traditional companies, with a positive outlook on the innovation theme in the long term [3][6] Group 4: Economic Data and Market Performance - The report includes key economic data releases from the US and China, with manufacturing and non-manufacturing PMI figures indicating varying market expectations [7] - The performance of major global indices is summarized, with the Hang Seng Index closing at 25,936, reflecting a year-to-date increase of 29.05% [4] - Commodity prices and foreign exchange rates are also provided, showing significant fluctuations in various markets, which may impact investment strategies [5]

Core Viewpoint - The Hong Kong stock market, particularly the innovative drug sector, is experiencing a significant rally, with institutions optimistic about the market's future trajectory despite previous adjustments, indicating a continuation of the long-term bull market [1][6][7]. Summary by Sections Innovative Drug Sector Performance - On December 4, the innovative drug sector in Hong Kong saw substantial gains, with companies like Gilead Sciences rising over 11%, and WuXi Biologics and WuXi AppTec increasing by over 7% [2]. - Other notable performers included companies like InnoCare Pharma and BeiGene, which also experienced significant increases [2]. Strategic Developments - WuXi Biologics announced a strategic cooperation memorandum with the Qatar Free Zone Authority, aiming to establish an integrated CRDMO center in the Middle East [4]. - According to research from CMB International, the overall orders and performance in the CXO sector are expected to recover significantly by 2025, driven by improved financing conditions and an increase in overseas demand [4]. Market Outlook and Analyst Recommendations - Analysts from Ping An Securities highlighted the optimization of the medical insurance fund structure and policies encouraging high-quality innovative drug development, suggesting a focus on companies with leading technological platforms in the CXO field [5]. - Nomura reiterated a "buy" rating for WuXi AppTec, raising its target price from HKD 130.63 to HKD 132.8, citing the company's strong R&D capabilities and significant project backlog [5]. - As of September 2025, WuXi Biologics has secured 3,430 projects, three times the number from 2021, with total order backlog reaching CNY 59.88 billion, and new orders increasing by 32% year-on-year [5]. Broader Market Trends - The Hong Kong stock market indices, including the Hang Seng Index and Hang Seng Tech Index, showed positive movements, with gains of 0.68% and 1.45% respectively on December 4 [6]. - Analysts predict a shift in investment logic from traditional valuation recovery to a revaluation based on new productivity and high-quality development, with expectations for moderate expansion in valuation and earnings in 2026 [6]. - The market is anticipated to benefit from internal catalysts and external economic policies, with a forecast for a second round of valuation recovery and further performance improvement in 2026 [7].